viewNetscientific PLC

NetScientific ‘totally revitalised’ under Francois Martelet, says chairman Sir Richard Sykes

“We now have a focused portfolio of assets which are close to commercialisation and which offer the scope for significant value creation,” Sykes said ahead of a Capital Markets Day.

represents meetings
Sykes and Martelet will outline the next steps for NetScientific

NetScientific Plc’s (LON:NSCI) management team and portfolio focus have been totally revitalised by Francois Martelet, who took up the position of chief executive last June.

That’s the view of the company’s chairman Sir Richard Sykes ahead of the company’s Capital Markets Day at the London Stock Exchange, which happens today.

“We now have a focused portfolio of assets which are close to commercialisation and which offer the scope for significant value creation,” Sykes said in a statement.

“We look forward to highlighting the key jewels in our crown, and to explaining how they offer opportunities both to provide patient benefit and shareholder value."

Sykes and Martelet will outline to attending investors the next steps for NetScientific in maximising value from its portfolio companies. The LSE organised event will also feature representatives from the businesses that NetScientific is invested in.

In a separate statement, NetScientific announced the appointment of Dr Massimo Cristofanilli by portfolio company Vortex Biosciences to be chairman of its newly formed scientific advisory board.

"Vortex Biosciences is at a pivotal point as its circulating tumour cell enrichment system, the VTX-1, moves towards commercialisation,” Martelet said.

“The appointment of Dr. Cristofanilli, who will be joining to spearhead the creation of Vortex's world class Scientific Advisory Board, will help underpin their clinical strategy as the company moves through this transformational period."

Quick facts: Netscientific PLC

Price: 64.58 GBX

Market: AIM
Market Cap: £9.63 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Netscientific PLC named herein, including the promotion by the Company of Netscientific PLC in any Content on the Site, the Company receives...


Investor Update: ANGLE reports positive data from Parsortix FDA clinical study

Top stories from the Proactive Investors UK newsroom: ANGLE PLC (LON:AGL) has received positive results from its Parsortix FDA clinical study for metastatic breast cancer. The 400-subject clinical study will support an application for Class II regulatory clearance for Parsortix in the...

on 31/5/19

2 min read